{
    "SPADE_N_14473": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_14473",
            "Peptide Name": "RK-9+ (Synthetic AMPs, LL-37 derived, Trp-rich, Lys-rich, XXA, UCLL1c; BBMm)",
            "Source": "amino acid truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "RWWKKWWGK",
            "Sequence Length": 9,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Anti-MRSA",
                "Antibiofilm"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 1360.61,
            "PI": 11.26,
            "Hydrophobicity": -2.24,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Mechesso AF, Zhang W, Su Y, Xie J, Wang G. 2024",
                    "Reference": "Probiotics Antimicrob Proteins. 2024 Oct 8. doi: 10.1007/s12602-024-10376-3.PubMed",
                    "Title": "Segment-Based Peptide Design Reveals the Importance of N-Terminal High Cationicity for Antimicrobial Activity Against Gram-Negative Pathogens."
                }
            ],
            "Frequent Amino Acids": "WKG",
            "Absent Amino Acids": "ACDEFHILMNOPQSTUVY",
            "Basic Residues": 4,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 4,
            "Polar Residues": 4,
            "Positive Residues": 4,
            "Negative Residues": 0,
            "Net Charge": 4,
            "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (70%) toWK2W: 44%, K: 33%, G=R: 11%. GRAVY: -2.24, mol Wt: 1360.617; mol formula: C70H97N19O10; mol ex coeff: 22200.Activity: active against  S. aureus USA300 MRSA (MIC 8 uM), S. epidermidis 1457 (MIC 16 uM), P. aeruginosa E411-17 (MIC 16 ug/ml), E. coli E423-17 (MIC 8 uM), and A-baumannii B28-16 (MIC >32 uM).Biofilms: Inhibited biofilm formation:bacteria:S. aureus; inhibited biofilm formation:bacteria:P. aeruginosa; disrupted preformed biofilm:bacteria:S. aureus; disrupted preformed biofilm:bacteria:P. aeruginosa;In vitro toxicity: human RBC: essentially not hemo.lytic till 400 uM. Not toxic to human keratinocyte HaCaT cells (LC50 > 100 uM), human hepatoma HepG2 cells (LC50 >100 uM), and human lung carcinoma A549 cells (LC50 >100 uM).MOA:bacteria:S. aureus USA300: membrane permeation.Animal model:mouse: wound healing model:S. aureus: ~2 logs CFU reduction after treatment once at 10 mg/kg.",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_14186",
                    "Similarity": 1.0,
                    "Sequence": "AGKETIRQFLKKKIQEKGKIATRWW"
                },
                {
                    "SPADE_ID": "SPADE_UN_02081",
                    "Similarity": 1.0,
                    "Sequence": "RSIMTQRWW"
                },
                {
                    "SPADE_ID": "SPADE_UN_02209",
                    "Similarity": 1.0,
                    "Sequence": "VRISIMRWW"
                }
            ]
        }
    }
}